Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic Control.
ACS Med Chem Lett November 10, 2025 DOI: 10.1021/acsmedchemlett.5c00661 (opens in new tab) via PubMed
Summary
AI-generated from the abstractRecent patents describe a new generation of psychedelic analogs designed to modulate the 5-HT2A receptor more precisely, with fewer side effects and adjustable duration. By modifying the chemical structures of DMT and psilocin—using prodrug strategies, adding fluorine atoms, and exploring structure-activity relationships—these innovations aim to create safer, shorter-acting psychedelic medications that fit better into clinical settings and offer more predictable therapeutic effects for psychiatric conditions.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Key finding | Patents describe psychedelic analogs optimized for 5-HT2A receptor modulation with reduced adverse effects and tunable duration of action. |
Abstract
High Resolution Image Download MS PowerPoint Slide Recent patents unveil a new wave of psychedelic analogs optimized for 5-HT 2 A receptor modulation, reduced adverse effects, and tunable duration of action. By refining DMT and psilocin scaffolds through prodrug design, fluorination, and structure–activity exploration, these innovations promise safer, shorter-acting psychedelic medicines that align with clinical workflow and improve therapeutic predictability for psychiatric disorders.